Nintedanib slows progression for broad range of scarring lung diseases

Nintedanib, a medication approved for the treatment of idiopathic pulmonary fibrosis, slows the decline in lung function among patients with a broad range of scarring lung diseases. The findings, published in the New England Journal of Medicine, suggest that many more people may benefit from nintedanib than are currently approved for treatment. They also suggest that the dozens of different forms of fibrosing interstitial lung disease may share similar scarring mechanisms in spite of different causes and patterns.